# Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF

> **NCT06660134** · NA · COMPLETED · sponsor: **Shanghai Chest Hospital** · enrollment: 174 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)
- Atrial Fibrillation (AF)

## Interventions

- **DRUG:** Glucagon-like peptide-1 receptor agonists (GLP 1 RA)

## Key facts

- **NCT ID:** NCT06660134
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-01-10
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2024-10-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660134, "Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06660134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*